Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial
Cancer · 15.08.2025 · 131 (16)
DOI: 10.1002/cncr.70046 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 17.08.2025. Verfasst von Ming Bai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's …. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Key Medical Discipline Construction Project, National Major Science and Technology Projects of China.
Abstract (Originalsprache)
Background
This trial evaluated the efficacy and safety of anti‐programmed cell death 1 antibody (SCT‐I10A) and anti‐epidermal growth factor receptor (EGFR) antibody (SCT200) in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC) (trial registration number: NCT04229537).
Methods
This multicenter, open‐label, phase 1b clinical trial enrolled patients with advanced ESCC refractory or intolerant to standard chemotherapy. Patients who had not received prior treatment with programmed death‐(ligand)1 (PD‐(L)1) immune checkpoint inhibitors (ICIs) or anti‐EGFR antibodies comprised cohort 1A, and those who had previously failed treatment with PD‐(L)1 ICIs or anti‐EGFR antibodies comprised cohort 1B. Eligible patients were treated with SCT200 and SCT‐I10A.
Results
Seventy patients were enrolled. The objective response rate was 25.7%, with a median overall survival and progression‐free survival of 6.90 months and 3.98 months, respectively. Twenty‐nine patients previously underwent ICI treatment with an objective response rate of 17.24%, median overall survival of 6.08 months, and median progression‐free survival of 3.98 months. Grade 3 or higher adverse events were observed in 43.3% and 52.5% of patients in cohort 1A and 1B, respectively.
Conclusions
SCT‐I10A plus SCT200 demonstrated durable antitumor activity with a manageable safety profile in previously treated patients with advanced ESCC, even in patients who had previously failed anti‐PD‐(L)1 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digesti…
- Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
- Department of Medical Oncology Gastroenterology and Urology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
- The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Luoyang, China.
- Department of Thoracic Cancer, Affiliated Hangzhou Cancer Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- 900 Hospital of the Joint Logistics Support Force, Fuzhou, China.
ORCID-Profile: Yi Ba
Förderung
- Tianjin Key Medical Discipline Construction Project
- National Major Science and Technology Projects of China
Zitieren
APA
Bai, M., Lu, Y., Shen, L., Yin, X., Gao, S., Xia, B., Fu, Z., Zhang, Z., Xie, L., & Ba, Y. (2025). Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial. Cancer, 131(16). https://doi.org/10.1002/cncr.70046
Vancouver
Bai M, Lu Y, Shen L, Yin X, Gao S, Xia B, et al. Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial. Cancer. 2025;131(16). doi:10.1002/cncr.70046
BibTeX
@article{Bai2025,
author = {Bai, Ming and Lu, Yao and Shen, Lin and Yin, Xianli and Gao, Shegan and Xia, Bing and Fu, Zhichao and Zhang, Zhen and Xie, Liangzhi and Ba, Yi},
title = {Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial},
journal = {Cancer},
year = {2025},
volume = {131},
number = {16},
doi = {10.1002/cncr.70046}
}
EUVIMED